Dianthus Therapeutics Files 2024 10-K
Ticker: DNTH · Form: 10-K · Filed: Mar 11, 2025 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | 10-K |
| Filed Date | Mar 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, partnerships, financials
TL;DR
Dianthus Therapeutics 2024 10-K is in! Check out their deals with Zenas Biopharma & Iontas.
AI Summary
Dianthus Therapeutics, Inc. filed its 2024 10-K on March 11, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Magenta Therapeutics, Inc., is involved in the pharmaceutical preparations industry. Key financial activities and agreements, including those with Zenas Biopharma Inc. and Iontas Limited, are detailed. The filing also covers stock option plans and various assets held as of year-end 2024.
Why It Matters
This filing provides a comprehensive overview of Dianthus Therapeutics' financial health, operational activities, and strategic partnerships for the fiscal year 2024, crucial for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and competitive pharmaceutical industry, facing risks related to drug development, clinical trials, and market adoption.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the financial statements in the 10-K.)
- 2025-03-11 — Filing Date (The date the 10-K was submitted to the SEC.)
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Filer of the 10-K
- Magenta Therapeutics, Inc. (company) — Former name of Dianthus Therapeutics, Inc.
- Zenas Biopharma Inc. (company) — Partner company mentioned in relation to license revenue and other agreements.
- Iontas Limited (company) — Partner company mentioned in relation to commercial milestones and development programs.
- 2024-12-31 (date) — Fiscal year end date for the reported period.
- 2025-03-11 (date) — Filing date of the 10-K.
FAQ
What was the primary business of Dianthus Therapeutics, Inc. in 2024?
Dianthus Therapeutics, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
What is the significance of the name change from Magenta Therapeutics, Inc.?
The company was formerly known as Magenta Therapeutics, Inc., with a name change effective November 21, 2016.
What are some key partnerships or agreements mentioned in the filing?
The filing mentions agreements and relationships with Zenas Biopharma Inc. and Iontas Limited, involving aspects like license revenue, commercial milestones, and upfront payments.
What types of assets does Dianthus Therapeutics hold as of December 31, 2024?
As of December 31, 2024, the company held assets including U.S. Treasury Securities and Money Market instruments, as well as Furniture and Fixtures.
Does the filing mention any stock incentive plans?
Yes, the filing references the 'TwoThousandAndEighteenStockOptionAndIncentivePlanMember' and 'us-gaap:EmployeeStockOptionMember'.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 11, 2025 regarding Dianthus Therapeutics, Inc. /DE/ (DNTH).